The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Phase I trial of a BCMA-CD3 bispecific antibody in R/R myeloma
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA discusses the preliminary findings of a Phase I study (NCT03269136) of elranatamab (PF-3135), a bispecific monoclonal antibody, in relapsed/refractory multiple myeloma (MM). Elranatamab targets BCMA, a highly expressed myeloma cell antigen, and CD3, enabling T cell cytotoxic targeting of myeloma cells. Subcutaneous (SC) dose escalation was carried out in 18 patients: no dose-limiting toxicities were observed and the maximum tolerated dose not reached. Adverse events were generally tolerable; the most common was cytokine release syndrome. The overall response rate was 75% when observing the top two dose levels only. SC dose escalation is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
